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Background/aim: To evaluate the predictability of vardenafil success in patients with erectile dysfunction (ED) by using cardiological
tests.
Materials and methods: Patients diagnosed with ED who did not benefit from lifestyle changes (n = 68) were evaluated with an
abridged 5-item version of the International Index of Erectile Function (IIEF-5). The pretreatment and posttreatment IIEF-5 scores
were compared with pretreatment data obtained from cardiological examinations.
Results: When pretreatment scores were compared with test parameters, mitral flow E/A ratio and tissue Doppler imaging (TDI) Eʹ/
Aʹ, exercise test duration, exercise capacity in MET, and percentage of maximum heart rate were found to be statistically significant.
Furthermore, there was a significant negative correlation between mitral flow E/A ratio, TDI Eʹ/Aʹ, exercise test duration, exercise
capacity in MET, and the difference in post- and pretreatment IIEF-5 scores.
Conclusion: As a diastolic function indicator, TDI Eʹ/Aʹ positively correlates with pretreatment IIEF-5 scores and negatively correlates
with the beneficial effect of vardenafil treatment. As a result, the cardiological status of the patient correlates with individual IIEF-5
scores, and it seems to be useful in predicting vardenafil success.
Key words: Erectile dysfunction, phosphodiesterase type 5 inhibitor, diastolic dysfunction

1. Introduction
Erectile dysfunction (ED) is a sexual dysfunction
characterized by the inability to develop or maintain
an adequate erection during sexual performance. It is
estimated that 150 million men worldwide have ED (1).
Its prevalence only increases with age. This increment is
probably due to the fact that prevalence of underlying
comorbidities, such as cardiovascular disease and diabetes
mellitus, increase with age (2). The first phosphodiesterase
type 5 inhibitor (PDE5I) for ED treatment available on
the market was sildenafil. Sildenafil revolutionized ED
treatment. Sildenafil, and later tadalafil and vardenafil,
proved highly efficacious in studies.
However, these drugs did not demonstrate the same
efficacy in all patients. It was seen that some patients
effectively used the drug, and some patients discontinued
usage because of inefficiency (3). Currently, urologists
cannot predict in which patient PDE5Is can be used
effectively.
Vascular pathologies are the most common etiological
factors in ED. Vascular pathologies can be diagnosed
* Correspondence: kursadzengin@gmail.com

by penile Doppler ultrasound and are subgrouped into
arteriogenic insufficiency and veno-occlusive dysfunction
(4). There is strong evidence of an association between
cardiovascular disease (CVD) and ED. The risk factors are
similar and lead to endothelial dysfunction (5). As a result,
CVD and ED frequently coexist (6).
In this study we evaluated all ED patients with serum
laboratory tests, an echocardiogram, and a treadmill
exercise test before prescribing vardenafil. The significance
of these tests in predicting the efficacy of drug was
evaluated.
2. Materials and methods
2.1. Study design and patient population
The study was approved by the local ethics committee of
Bozok University (604/02-2013).
Patients with ED complaints who did not benefit
from lifestyle changes were evaluated with a full physical
examination, basic neurologic and psychiatric assessments
(suspected cases were presented to specialists), complete
blood count, fasting blood glucose, serum lipid profile,

751

ZENGİN et al. / Turk J Med Sci
hormonal profile with total testosterone, prolactin,
thyroid-stimulating hormone, an abridged 5-item
version of the International Index of Erectile Function
(IIEF-5), cardiology consultation, electrocardiogram
(ECG), echocardiogram, and a treadmill exercise test
on the first visit. Patients with surgical conditions of ED
(hypospadias, congenital penile curvature, Peyronie’s
disease), hormonal or neurologic pathologies, serious
cardiovascular disease, a history of previous PDE5I usage,
and who were on medications that may cause ED (e.g.,
diuretics, antidepressants, antiandrogens, antipsychotics)
were excluded from the study. The patients treated with
vardenafil were then reevaluated after 2 months (with
usage of at least 8 pills of vardenafil). Their IIEF-5 scores
were assessed again.
This study was conducted between June and December
2013. There were 132 patients diagnosed with ED during
this period. Thirty-six of the patients had used PDE5Is
before, 12 patients were using nitrates or were diagnosed
with cardiac instability by cardiologist, 4 patients had
histories of cerebrovascular accident, and 4 patients had
hyperprolactinemia or thyroid hormone abnormalities;
they were excluded from the study. There were 76 patients
with primary ED. Eight patients did not come to the
follow-up visit after 2 months, so the study group was
created from 68 patients.
2.2. Cardiological tests
Resting ECGs of all patients and controls were obtained
after a rest of 5 min in the room. A Modified Bruce
treadmill protocol was used to assess exercise capacity and
heart rate recovery (Quinton Q-Stress 4.0, 2008; Cardiac
Science Corporation, Germany). The test was stopped due
to either patient’s demand or reaching maximal targeted
heart rate (220 – age in years). None of the patients
revealed ischemic changes in the exercise treadmill test.
Heart rate recovery (HRR) was defined as the difference
between heart rate at peak exercise and at both the first
(HRR1) and second (HRR2) minutes after exercise.
Maximal heart rate in percent of targeted heart rate,
rate-pressure product (heart rate × blood pressure at the
moment of maximal exercise), maximal exercise capacity
in the standard metabolic equivalent (MET) (defined as
the amount of oxygen consumed at rest, sitting quietly in
a chair, approximately 3.5 mL O2 kg–1 min–1 (1.2 kcal/min
for a 70-kg person)), and exercise duration derived from
exercise treadmill test were used for analysis.
In the echocardiographic examination (Presound
Alpha 7, IPF 1701 Model, 2009; Hitachi Aloka Medical,
Ltd., Japan), left ventricle dimensions, and posterior
wall and interventricular septum diastolic thicknesses
were measured at M-mode images. Left atrial size (LA)
was measured at the aortic sinus Valsalva level by using
M-mode images. From the images of apical two- and four-
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chamber echo windows, LV ejection fractions (LVEFs)
were obtained using a modified Simpson method and
the average of two values was determined as the LVEF.
In an apical four-chamber window, by using pulse wave
(PW) Doppler, samples of transmitral diastolic inflow
were obtained and then mitral E and A waves were
measured. E/A ratios of all patients were calculated. All
measurements were carried out at the end of expiration.
By using PW tissue Doppler imaging (TDI), all diastolic
and systolic myocardial velocities were obtained. In this
study, to make the evaluation simple, a sample volume at
the LV lateral wall basal segment was used to obtain Eʹ
and Aʹ wave velocities in an apical four-chamber window.
E/Eʹ ratios were calculated accordingly. Pulmonary artery
systolic pressure of every patient was measured indirectly
by using tricuspid valve continuous wave velocity at the
apical four-chamber view. In the apical five-chamber view,
left ventricle outflow tract diameter (LVOT) and timevelocity integral (TVI) of pulse wave sample volume at
left ventricle outflow were used to measure stroke volume
(SV) by using the formula of SV (mL) = 3.14 × (LVOT/2)2
× TVI. SV divided by body surface area yielded cardiac
index. All Doppler measurements were carried out for five
subsequent cycles and the average of all five measurements
was used for statistical analysis.
2.3. Statistical analysis
The data obtained were analyzed with SPSS 18. Whether
quantitative variables had normal distribution was tested
with the Kolmogorov–Smirnov test. Except for diastolic
blood pressure, Eʹ/Aʹ ratio, and exercise capacity in
MET, all variables had normal distribution. Continuous
variables were expressed as mean ± standard deviation,
while categorical variables were shown as frequency
and percentage. In comparison of groups with normally
distributed variables, independent t-test or ANOVA
were used accordingly, while the Mann–Whitney U-test
was used for variables without normal distribution.
For correlation analysis of IIEF-5 values with ECG,
exercise test, and blood chemistry parameters, Pearson’s
correlation was carried out for normally distributed data,
while Spearman’s correlation was used for others. For all
analysis, P < 0.05 was accepted as statistically significant.
3. Results
The mean age of patients was 54.5 ± 8.1 years. The
demographical data are summarized in Table 1. The
mean pretreatment IIEF-5 score was 9.1 ± 2.5, and
the posttreatment score was 17.9 ± 2.7. There was a
statistically significant difference between posttreatment
and pretreatment IIEF-5 scores (P < 0.01). The severity
level of pretreatment and posttreatment ED was classified
according to the description of Rosen et al. (7). Table 2
summarizes pre- and posttreatment levels of ED.
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Table 1. Demographical data and erectile dysfunction scores of the patients.
N = 68

Mean ± SD

Age (years)

54.5 ± 8.1

Weight (kg)

80.8 ± 11.9

Height (m)

1.72 ± 0.07

BMI (kg/m2)

27.3 ± 3.5

SBP (mmHg)

111 ± 13

DBP (mmHg)

75 ± 8

Pretreatment IIEF-5 score

9.1 ± 2.5

Posttreatment IIEF-5 score

17.9 ± 2.7

Difference between post- and pretreatment IIEF-5 scores

8.8 ± 2.7

SBP: Systolic blood pressure, DBP: diastolic blood pressure, BMI: body mass index,
IIEF-5: International Index of Erectile Function.
Table 2. Pre- and posttreatment levels of ED.
Level of ED

Pretreatment n (%)

Posttreatment n (%)

Severe

12 (22%)

0

Moderate

29 (54%)

3 (6%)

Mild–moderate

13 (24%)

10 (18%)

Mild

0

39 (72%)

No ED

0

2 (4%)

ED: Erectile dysfunction.

The serum laboratory, echocardiographic examination,
and treadmill exercise test results are summarized in Table
3. In the echocardiographic examination, mean LVEF was
62.5 ± 2.7%. The mean treadmill exercise test duration was
10.4 ± 2.3 min.
Pretreatment IIEF-5 score and differences between
post- and pretreatment IIEF-5 scores were compared with
age, body mass index, systolic blood pressure, and diastolic
blood pressure as demographical data. The statistical
analysis revealed significance only with age, and there was
a negative correlation between age and pretreatment IIEF5 scores (P < 0.005, r = –0.539). There was also a statistically
significant positive correlation between difference in IIEF5 scores and age (P < 0.05, r = 0.365).
When pretreatment IIEF-5 scores were compared
with echocardiographic parameters, mitral flow E/A ratio
and TDI Eʹ/Aʹ were statistically significant (P < 0.001,
r = 0.636; P < 0.001, r = 0.862). Furthermore, there was
a significant negative correlation between mitral flow

E/A ratio, TDI Eʹ/Aʹ, and the difference in post- and
pretreatment IIEF-5 scores (P < 0.005, r = –0.487; P <
0.001, r = –0.569).
Similarly, pretreatment and difference in post- and
pretreatment IIEF-5 scores were compared with the
parameters obtained from treadmill exercise test. Exercise
test duration, exercise capacity in MET, and percentage
of maximum heart rate were statistically significant when
compared with pretreatment IIEF-5 scores (P < 0.005, r =
0.486; P < 0.01, r = 0.461; P < 0.05, r = 0.418). There was
a positive correlation observed in all of these statistically
significant variables. When we compared the difference in
post- and pretreatment IIEF-5 scores with these variables,
it was seen that there was a statistically significant negative
correlation observed in exercise test duration and exercise
capacity in MET (P < 0.05, r = –0.401; P < 0.05, r = –0.363).
To clarify these findings and to describe a cut-off value
for exercise test duration, we further analyzed the results.
We grouped the patients according to their exercise test
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Table 3. Laboratory, echocardiographic examination, and treadmill exercise test results of patients.
Parameter

Mean ± SD

Total testosterone (mg/dL)

612 ± 133

Triglyceride (mg/dL)

176 ± 104

Total Cholesterol (mg/dL)

201 ± 32

LDL(mg/dL)

129 ± 24

HDL (mg/dL)

40 ± 8

Prolactin (ng/mL)

8.6 ± 4.0

TSH (uIU/mL)

1.39 ± 0.55

FBG (mg/dL)

108 ± 29

Hgb (g/dL)

14.5 ± 0.9

LVEF (%)

62.5 ± 2.7

LA diameter (cm)

3.98 ± 0.31

PASB (mmHg)

24.6 ± 3.6

Mitral flow E/A ratio

1.13 ± 0.52

TDI Eʹ/Aʹ ratio

1.03 ± 0.49

E/Eʹ ratio

6.0 ± 1.6

Stroke volume (mL)

71.9 ± 15.2

Cardiac index (mL/m2)

36.5 ± 9.2

Exercise test duration (min)

10.4 ± 2.3

Exercise capacity in MET

11.0 ± 2.1

Cardiovascular product (mmHg × bpm)

25565 ± 4672

Percentage of max heart rate (%)

95 ± 6

HRR1 (beats/min)

28 ± 10

HRR2 (beats/min)

48 ± 11

Pretreatment
IIEF-5 score
P < 0.05
r = 0.424
P = 0.846
r = 0.036
P = 0.676
r = 0.077
P = 0.815
r = 0.043
P = 0.749
r = 0.059
P = 0.134
r = –0.271
P = 0.633
r = 0.088
P = 0.916
r = –0.019
P = 0.220
r = 0.223
P = 0.596
r = 0.094
P = 0.341
r = –0.168
P = 0.295
r = –0.185
P < 0.001
r = 0.636
P < 0.001
r = 0.862
P = 0.080
r = –0.305
P = 0.755
r = –0.055
P = 0.608
r = –0.105
P < 0.005
r = 0.486
P < 0.01
r = 0.461
P = 0.408
r = 0.163
P < 0.05
r = 0.418
P = 0.477
r = 0.140
P = 0.270
r = 0.216

Difference between post- and
pretreatment IIEF-5 scores
P < 0.05
r = –0.350
P = 0.728
r = –0.064
P = 0.160
r = –0.255
P = 0.371
r = –0.164
P = 0.902
r = 0.023
P < 0.05
r = 0.364
P = 0.291
r = 0.192
P = 0.082
r = –0.312
P = 0.142
r = –0.265
P = 0.394
r = –0.151
P = 0.713
r = –0.066
P = 0.123
r = 0.269
P < 0.005
r = –0.487
P < 0.001
r = –0.569
P = 0.768
r = 0.052
P = 0.960
r = 0.009
P = 0.891
r = 0.028
P < 0.05
r = –0.401
P < 0.05
r = –0.363
P = 0.428
r = –0.156
P = 0.333
r = –0.194
P = 0.694
r = 0.078
P = 0.450
r = 0.149

LDL: Low-density lipoprotein, HDL: high-density lipoprotein, TSH: thyroid-stimulating hormone, FBG: fasting blood glucose, Hgb:
hemoglobin, LVEF: left ventricle ejection fraction, LA diameter: left atrium diameter, PASB: pulmonary artery systolic pressure, TDI Eʹ/
Aʹ ratio: left ventricle lateral wall basal segment tissue Doppler imaging Eʹ/Aʹ ratio, E/E’ ratio: mitral flow E/TDI Eʹ ratio, Percentage of
max heart rate: percentage of achieved heart rate at maximum exercise level compared to targeted heart rate, MET: metabolic equivalent of
task, HRV: heart rate recovery, Cardiovascular product: product of heart rate × systolic blood pressure at maximum exercise level (mmHg
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duration. We observed that pretreatment IIEF-5 scores
were higher in patients with exercise test durations of
longer than 10 min (n = 32, mean ± SD = 10.1 ± 2.8) than
in patients with exercise test durations shorter than 10 min
(n = 36, mean ± SD = 8.2 ± 1.9) (P < 0.05). The difference
in post- and pretreatment IIEF-5 scores was lower in
patients with exercise test durations of longer than 10 min
than in patients with exercise durations pf shorter than 10
min (mean ± SD = 7.6 ± 2.9 vs. 9.8 ± 1.7, P < 0.05).
The relation between the severity of pretreatment
ED and the difference between post- and pretreatment
IIEF-5 scores were compared with the TDI Eʹ/Aʹ ratio
by using one-way ANOVA and Student’s t-test. Both the
pretreatment severity and the difference in IIEF-5 scores
were found as statistically significant, as demonstrated in
the Figure (P < 0.001; P < 0.005).
4. Discussion
The coexistence of CVD and ED has been subjected to
different studies. It was shown that these entities have
similar risk factors and a strong correlation (5,6). The
severity of CVD and ED was studied by Canat et al. They
reported a statistically significant correlation between
number of occluded coronary arteries and presence of
hypertension with ED (8).
Solak et al. reported a higher incidence of CVD in ED
patients. They also reported that ED is more frequent in
patients with chest pains of cardiac origin (9). The quality
of erection was assessed with the IIEF-5 in ischemic
heart disease (IHD) patients, and they were subjected

to a 6-month cardiac rehabilitation exercise schedule to
investigate the efficacy for changes in quality of erection.
The study group (IHD patients with similar characteristics
who are subjected to cardiac rehabilitation exercise) was
compared with a control group. The study drew two
conclusions: in the patients with IHD, erection quality
was significantly correlated with exercise tolerance; and
the cardiac rehabilitation exercise schedule had a positive
effect both on exercise tolerance and erection quality.
The Figure illustrates the relation between the severity
of ED and TDI Eʹ/Aʹ ratio, and the relation between the
difference of post- and pretreatment IIEF-5 scores and
TDI Eʹ/Aʹ ratio. The TDI Eʹ/Aʹ ratio is an indicator of
diastolic dysfunction. As the TDI Eʹ/Aʹ ratio decreases
below 1, the severity of diastolic dysfunction increases.
Statistical analysis revealed a significant difference and a
positive correlation between the pretreatment scores of
IIEF-5 and TDI Eʹ/Aʹ ratio. In the Figure, it is also seen
that there is a statistically significant difference between
the improvement in posttreatment IIEF-5 scores and TDI
Eʹ/Aʹ ratio (P = 0.005). The results revealed that as the
degree of diastolic dysfunction increases, the severity
of ED increases in the same manner. Likewise, when we
grouped the patients as TDI Eʹ/Aʹ ratio below 1 (mean
pretreatment IIEF-5 score = 7.3 ± 1.5; difference between
post- and pretreatment IIEF-5 scores = 10.1 ± 2.0), and
over 1 (mean pretreatment IIEF-5 score = 11.4 ± 1.5;
difference between post- and pretreatment IIEF-5 scores =
7.2 ± 2.8), the patients who had diastolic dysfunction (with
TDI Eʹ/Aʹ ratio below 1) responded better to vardenafil

1.6

16
P < 0.001
Improvement in IIEF5 scores posttreatment

1.4

TDI E’/A’ ratio

1.2
1.0
0.8
0.6
0.4

12
10
8
6
4
2

0.2
0.0

P < 0.005

14

0
Severe ED

Moderate ED
Mild-Moderate ED
Erectile Dysfunction Severity

<1

≥1
TDI E’/A RATIO

Figure. The relationship between the severity of pretreatment ED, the difference between post and pretreatment IIEF-5 scores, and
TDI Eʹ/Aʹ ratio.
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treatment (P < 0.005).
HRR1 and HRR2 are parameters related to autonomic
dysfunction. The normal range of HRR1 is over 12 beats/min.
A result of 12 beats/min or below is an indicator of autonomic
dysfunction in patients (10). In our patient population, the
mean value of HRR1 was 28 ± 10 beats/min. None of our
patients were in the limits of autonomic dysfunction. Doğru
et al. reported the presence of autonomic dysfunction in
ED patients (11). When we compared HRR1 values and
pretreatment IIEF-5 scores, we did not find any significant
difference, but there was a weak positive correlation (P =
0.477, r = 0.140). When we subgrouped patients according
to the severity of ED, the mean values of HRR1 in severe
and moderate ED patients were 22.7 ± 3.6, and 30.1 ± 11.8,
respectively. The comparison of severe and moderate ED
patients by means of HRR1 yielded a statistically significant
difference (P < 0.05). These results demonstrated that if the
severity of ED increases, HRR1 as an indicator of autonomic
dysfunction decreases. In the study by Doğru et al., patients
were only classified as having ED or not; there was no
subgrouping such as severe, moderate, and mild. This was
the probable cause of statistically significant values gathered
in their study.
The endothelium is the major contributor of vascular
homeostasis; it provides vasodilatation, inhibition of
inflammation, and suppression of smooth muscle growth.
These effects are mostly mediated by nitric oxide. Nitric
oxide inhibits atherosclerosis by providing vasodilatation,
decreases low-density lipoprotein oxidation, reduces
platelet aggregation to the endothelium, inhibits smooth
muscle proliferation, and prevents leukocyte adhesion and
infiltration into the vessel (12).
Flow-mediated dilatation (FMD) is the most widely
used noninvasive test for assessing endothelial function. In
a prior study, ED severity, clinical response to PDE5I, and
structural/vascular changes in hypertensive patients were
evaluated. Responders to vardenafil were younger and had
a lower cardiovascular risk profile, higher FMD in brachial
artery, and higher baseline IIEF-5 score. The study also
noted that intima-media thickness of the carotid artery
was an independent factor associated with ED severity,
and FMD was the best predictor of clinical response to

vardenafil. The study revealed that even though there
was no clinical sign of vasculogenic dysfunction, ED was
associated with vascular changes, probably because of
endothelial dysfunction (13). In our study, none of the
patients had systolic dysfunction or known vasculogenic
disease, but results showed a statistical correlation between
diastolic dysfunction parameters and baseline IIEF-5
scores. Patients with worse diastolic functions had lower
baseline IIEF-5 scores and responded better to vardenafil
treatment.
Systolic dysfunction causes decrement in exercise
capacity, as measured by the treadmill exercise test. In
our patient population, ejection fraction and stroke
volume values were within the normal range, and cardiac
instability was one of our exclusion criteria. Based on these
variables, we can conclude that none of our patients had
clinical systolic dysfunction. Exercise test duration and
exercise capacity in MET are parameters directly related
with exercise capacity. Diastolic dysfunction also causes
decrement in exercise capacity.
It can be said that the difference between post- and
pretreatment IIEF-5 values shows us the beneficial effects
of treatment. With the help of correlation analysis, we can
propose that treadmill exercise test duration has a positive
significant correlation with pretreatment IIEF-5 scores
and a negative significant correlation with the difference of
post- and pretreatment IIEF-5 scores. This indicates that in
the patients with better cardiac performance, pretreatment
IIEF-5 scores were higher, and if the treadmill exercise
test duration of the patient is lower, the beneficial effect
of vardenafil becomes more evident. The same correlation
was seen also in exercise capacity in MET.
In the present study, the patients had neither systolic
dysfunction nor significant diastolic dysfunction. As
a diastolic function indicator, TDI Eʹ/Aʹ positively
correlates with pretreatment IIEF-5 scores and negatively
correlates with the beneficial effect of vardenafil treatment.
Similarly, it seems that cardiac performance is positively
correlated with pretreatment IIEF-5 scores and negatively
correlated with the beneficial effect of vardenafil treatment.
As a result, the cardiological status of the patient correlates
with individual IIEF-5 scores, and it seems to be useful in
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